PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Alterations in cell cycle regulators have been implicated in human malignancies including breast cancer. PD 0332991 is an orally active, highly selective inhibitor of the cyclin D kinases (CDK)4 and CDK6 with ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. To identify predictors of response, we determined the in vitro sensitivity to PD 0332991 across a panel of molecularly characterized human breast cancer cell lines. METHODS: Forty-seven human breast cancer and immortalized cell lines representing the known molecular subgroups of breast cancer were treated with PD 0332991 to determine IC50 values. These data were analyzed against baseline gene expression data to identify genes associated with PD 0332991 response. RESULTS: Cell lines representing luminal estrogen receptor-positive (ER+) subtype (including those that are HER2 amplified) were most sensitive to growth inhibition by PD 0332991 while nonluminal/basal subtypes were most resistant. Analysis of variance identified 450 differentially expressed genes between sensitive and resistant cells. pRb and cyclin D1 were elevated and CDKN2A (p16) was decreased in the most sensitive lines. Cell cycle analysis showed G0/G1 arrest in sensitive cell lines and Western blot analysis demonstrated that Rb phosphorylation is blocked in sensitive lines but not resistant lines. PD 0332991 was synergistic with tamoxifen and trastuzumab in ER+ and HER2-amplified cell lines, respectively. PD 0332991 enhanced sensitivity to tamoxifen in cell lines with conditioned resistance to ER blockade. CONCLUSIONS: These studies suggest a role for CDK4/6 inhibition in some breast cancers and identify criteria for patient selection in clinical studies of PD 0332991
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In some of these models, resistance can be overcome by including CDK4/6 inhibitors in the treatment (Finn et al., 2009; Goel et al., 2016; Kwong et al., 2012; Vora et al., 2014; Zhou et al., 2017).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Finn et al., 2009
In the citing paper
“Preclinical data utilizing palbociclib demonstrated the substantial sensitivity of hormone receptor (HR)-positive cell lines, compared to HR-negative cell lines, in part related to a higher incidence of RB-negativity in the latter breast cancer subgroup (81).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Trastuzumab has been shown to have clinical activity in HER2amplified breast cancer [34].”
BackgroundSelf-citationSørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“Multiple drug effect analysis was performed using computer software as previously described [33].”
MethodA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 1×
“PD 0332991 is an orally active potent and highly selective inhibitor of CDK4 and CDK6 kinases, which in low nanomolar concentrations blocks pRb phosphorylation - subsequently inducing G1 arrest in sensitive cell lines [26-29].”
Background
Research works printed but not linked: 1
- Duchnowska RJJ, Thorat MA, Morimiya A, Sledge GW, Li L, Biernat W, Szczylik C, Steeg PS, Badve SS: Gene expression analysis for prediciton of early brain metastasis in HER2-positive breast cancer patients [abstract 1019]. J Clin Oncol. 2008, 26 (20 Suppl): abstract 1019
Cited by
Items 101–200 of 1,000
Finn, R. S., Liu, Y., Zhu, Z., Martin, M., Rugo, H. S., Diéras, V., Im, S.-A., Gelmon, K. A., Harbeck, N., Lu, D. R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0751 · Cited by 201
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
Schettini, F., De Santo, I., Rea, C. G., De Placido, P., Formisano, L., Giuliano, M., Arpino, G., De Laurentiis, M., Puglisi, F., De Placido, S., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00608 · Cited by 201
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer
Slamon, D. J., Diéras, V., Rugo, H. S., Harbeck, N., Im, S.-A., Gelmon, K. A., Lipatov, O. N., Walshe, J. M., Martin, M., Chavez-MacGregor, M., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.00137 · Cited by 200
Self-citationTargeting the RB-E2F pathway in breast cancer
Johnson, J., Thijssen, B., McDermott, U., Garnett, M., Wessels, L. F. A., & Bernards, R. (2016) · Oncogene · doi:10.1038/onc.2016.32 · Cited by 199
Araki, K., & Miyoshi, Y. (2018) · Breast Cancer · doi:10.1007/s12282-017-0812-x · Cited by 196
Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer
Kinnel, B., Singh, S. K., Oprea-Ilies, G., & Singh, R. (2023) · Cancers · doi:10.3390/cancers15041320 · Cited by 184
CDK4: A Key Player in the Cell Cycle, Development, and Cancer
Baker, S. J., & Reddy, E. P. (2012) · Genes & Cancer · doi:10.1177/1947601913478972 · Cited by 194
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor
Freeman-Cook, K., Hoffman, R. L., Miller, N., Almaden, J., Chionis, J., Zhang, Q., Eisele, K., Liu, C., Zhang, C., Huser, N., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.009 · Cited by 189
Ding, M. Q., Chen, L., Cooper, G. F., Young, J. D., & Lu, X. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0378 · Cited by 188
Nebenfuehr, S., Kollmann, K., & Sexl, V. (2020) · International Journal of Cancer · doi:10.1002/ijc.33054 · Cited by 187
Finn, R. S., Crown, J. P., Ettl, J., Schmidt, M., Bondarenko, I. M., Lang, I., Pinter, T., Boer, K., Patel, R., Randolph, S., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0721-5 · Cited by 186
Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy
Knudsen, E. S., Pruitt, S. C., Hershberger, P. A., Witkiewicz, A. K., & Goodrich, D. W. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.03.005 · Cited by 185
Targeting the cell cycle in breast cancer: towards the next phase
Thu, K., Soria-Bretones, I., Mak, T., & Cescon, D. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1502567 · Cited by 185
Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present
Casimiro, M. C., Velasco-Velázquez, M., Aguirre-Alvarado, C., & Pestell, R. G. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.867017 · Cited by 184
Current and Future Management of HER2-Positive Metastatic Breast Cancer
Martínez-Sáez, O., & Prat, A. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00172 · Cited by 183
VIEDMA-RODRÍGUEZ, R., BAIZA-GUTMAN, L., SALAMANCA-GÓMEZ, F., DIAZ-ZARAGOZA, M., MARTÍNEZ-HERNÁNDEZ, G., ESPARZA-GARRIDO, R. R., VELÁZQUEZ-FLORES, M. A., & ARENAS-ARANDA, D. (2014) · Oncology Reports · doi:10.3892/or.2014.3190 · Cited by 182
McCartney, A., Migliaccio, I., Bonechi, M., Biagioni, C., Romagnoli, D., De Luca, F., Galardi, F., Risi, E., De Santo, I., Benelli, M., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00666 · Cited by 180
Spring, L. M., Zangardi, M. L., Moy, B., & Bardia, A. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0142 · Cited by 178
Cell cycle regulators in cancer cell metabolism
Leal-Esteban, L. C., & Fajas, L. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165715 · Cited by 179
Aftimos, P., Oliveira, M., Irrthum, A., Fumagalli, D., Sotiriou, C., Gal-Yam, E. N., Robson, M. E., Ndozeng, J., Di Leo, A., Ciruelos, E. M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1647 · Cited by 179
Harbeck, N., Iyer, S., Turner, N., Cristofanilli, M., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Bhattacharyya, H., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw139 · Cited by 176
Hu, W., Sung, T., Jessen, B. A., Thibault, S., Finkelstein, M. B., Khan, N. K., & Sacaan, A. I. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1421 · Cited by 171
Gianni, L., Bisagni, G., Colleoni, M., Del Mastro, L., Zamagni, C., Mansutti, M., Zambetti, M., Frassoldati, A., De Fato, R., Valagussa, P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30001-9 · Cited by 172
Finn, R. S., Boer, K., Bondarenko, I., Patel, R., Pinter, T., Schmidt, M., Shparyk, Y. V., Thummala, A., Voitko, N., Bananis, E., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05755-7 · Cited by 171
CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions
Spring, L. M., Wander, S. A., Zangardi, M., & Bardia, A. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0769-3 · Cited by 170
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 170
Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
Hart, C. D., Migliaccio, I., Malorni, L., Guarducci, C., Biganzoli, L., & Di Leo, A. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.99 · Cited by 169
The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D
Chaikovsky, A. C., Li, C., Jeng, E. E., Loebell, S., Lee, M. C., Murray, C. W., Cheng, R., Demeter, J., Swaney, D. L., Chen, S.-H., et al. (2021) · Nature · doi:10.1038/s41586-021-03474-7 · Cited by 167
Recent advances of highly selective CDK4/6 inhibitors in breast cancer
Xu, H., Yu, S., Liu, Q., Yuan, X., Mani, S., Pestell, R. G., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0467-2 · Cited by 168
“lymphoblastic leukemia (T-ALL) [45], hepatocellular carcinoma [39], neuroblastoma [40], renal cell carcinoma [52], myeloma [53], mantle cell lymphoma [54], pancreatic ductal adenocarcinoma [49], esophageal adenocarcinoma [55], medulloblastoma [51], melanoma [56], non-small cell lung carcinoma [57], and particularly in…”
BackgroundInfluentialUpdates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
Sobhani, N., D’Angelo, A., Pittacolo, M., Roviello, G., Miccoli, A., Corona, S. P., Bernocchi, O., Generali, D., & Otto, T. (2019) · Cells · doi:10.3390/cells8040321 · Cited by 167
Chambers, C. R., Ritchie, S., Pereira, B. A., & Timpson, P. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13042 · Cited by 165
Targeting CDK6 in cancer: State of the art and new insights
Tadesse, S., Yu, M., Kumarasiri, M., Le, B. T., & Wang, S. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1084445 · Cited by 163
Recent progress of CDK4/6 inhibitors’ current practice in breast cancer
Wang, X., Zhao, S., Xin, Q., Zhang, Y., Wang, K., & Li, M. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00747-x · Cited by 163
Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer
Portman, N., Alexandrou, S., Carson, E., Wang, S., Lim, E., & Caldon, C. E. (2019) · Endocrine-Related Cancer · doi:10.1530/erc-18-0317 · Cited by 163
Malorni, L., Piazza, S., Ciani, Y., Guarducci, C., Bonechi, M., Biagioni, C., Hart, C. D., Verardo, R., Leo, A. D., & Migliaccio, I. (2016) · Oncotarget · doi:10.18632/oncotarget.12010 · Cited by 162
CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1
Liu, T., Yu, J., Deng, M., Yin, Y., Zhang, H., Luo, K., Qin, B., Li, Y., Wu, C., Ren, T., et al. (2017) · Nature Communications · doi:10.1038/ncomms13923 · Cited by 161
Siemeister, G., Lücking, U., Wengner, A. M., Lienau, P., Steinke, W., Schatz, C. A., Mumberg, D., & Ziegelbauer, K. B. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0286 · Cited by 176
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
Corona, S. P., & Generali, D. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s137783 · Cited by 157
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
He, S., Roberts, P. J., Sorrentino, J. A., Bisi, J. E., Storrie-White, H., Tiessen, R. G., Makhuli, K. M., Wargin, W. A., Tadema, H., van Hoogdalem, E.-J., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3986 · Cited by 156
Wang, S., Yuan, X., Wang, S., Zhao, W. H., Chen, X., & Yu, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113218 · Cited by 169
What Is Known about Breast Cancer in Young Women?
Zhu, J. W., Charkhchi, P., Adekunte, S., & Akbari, M. R. (2023) · Cancers · doi:10.3390/cancers15061917 · Cited by 225
Palbociclib: First Global Approval
Dhillon, S. (2015) · Drugs · doi:10.1007/s40265-015-0379-9 · Cited by 175
Wardell, S. E., Ellis, M. J., Alley, H. M., Eisele, K., VanArsdale, T., Dann, S. G., Arndt, K. T., Primeau, T., Griffin, E., Shao, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0360 · Cited by 155
Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies
Saatci, Ö., Huynh‐Dam, K., & Şahin, Ö. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02136-5 · Cited by 190
Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition
Dean, J. L., McClendon, A. K., & Knudsen, E. S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.365494 · Cited by 155
Millour, J., Constantinidou, D., Stavropoulou, A. V., Wilson, M. S. C., Myatt, S. S., Kwok, J. M.-M., Sivanandan, K., Coombes, R. C., Medema, R. H., Hartman, J., et al. (2010) · Oncogene · doi:10.1038/onc.2010.47 · Cited by 155
Yoshida, A., Lee, E. K., & Diehl, J. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2931 · Cited by 153
The potential of activator protein 1 (AP-1) in cancer targeted therapy
Song, D., Lian, Y., & Zhang, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1224892 · Cited by 179
Lok, S. W., Whittle, J. R., Vaillant, F., Teh, C. E., Lo, L. L., Policheni, A. N., Bergin, A. R. T., Desai, J., Ftouni, S., Gandolfo, L. C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1151 · Cited by 148
“While CDK4/6 inhibitors elicit potent anti-proliferative effects, they do not induce tumor cell death (9).”
BackgroundCaldon, C. E., Sergio, C. M., Kang, J., Muthukaruppan, A., Boersma, M. N., Stone, A., Barraclough, J., Lee, C. S., Black, M. A., Miller, L. D., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0963 · Cited by 151
Targeted therapy for breast cancer: An overview of drug classes and outcomes
Jacobs, A. T., Castaneda-Cruz, D. M., Rose, M. M., & Connelly, L. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115209 · Cited by 173
Kang, J., Sergio, C. M., Sutherland, R. L., & Musgrove, E. A. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-32 · Cited by 152
The application and prospect of CDK4/6 inhibitors in malignant solid tumors
Du, Q., Guo, X. Y., Wang, M., Li, Y., Sun, X., & Li, Q. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00880-8 · Cited by 166
Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs
Yuan, K., Wang, X., Dong, H., Min, W., Hao, H., & Yang, P. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.05.001 · Cited by 156
Lange, C. A., & Yee, D. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-11-0112 · Cited by 147
Watt, A. C. S., & Goel, S. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01510-6 · Cited by 173
O’Brien, N. A., McDermott, M. S. J., Conklin, D. F., Luo, T., Ayala, R., Salgar, S., Chau, K., DiTomaso, E., Babbar, N., Su, F., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01320-8 · Cited by 155
Steinebach, C., Ng, Y. L. D., Sosič, I., Lee, C.-S., Chen, S., Lindner, S., Vu, L. P., Bricelj, A., Haschemi, R., Monschke, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc00167h · Cited by 148
Miller, T., & Hosford, S. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s52762 · Cited by 141
Endocrine treatment in breast cancer: Cure, resistance and beyond
Tryfonidis, K., Zardavas, D., Katzenellenbogen, B. S., & Piccart, M. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.08.008 · Cited by 153
LncMAP: Pan-cancer atlas of long noncoding RNA-mediated transcriptional network perturbations
Li, Y., Li, X., Wang, Z., Pan, T., Sahni, N., Jin, X., Wang, G., Li, J., Zheng, X., Zhang, Y., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1311 · Cited by 157
Cdk4 and Cdk6 Couple the Cell-Cycle Machinery to Cell Growth via mTORC1
Romero‐Pozuelo, J., Figlia, G., Kaya, O., Martín-Villalba, A., & Teleman, A. A. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.068 · Cited by 142
Lozano-Torres, B., Estepa-Fernández, A., Rovira, M., Orzáez, M., Serrano, M., Martínez-Máñez, R., & Sancenón, F. (2019) · Nature Reviews Chemistry · doi:10.1038/s41570-019-0108-0 · Cited by 140
A proteome-wide atlas of drug mechanism of action
Mitchell, D. C., Kuljanin, M., Li, J., Vranken, J. G. V., Bulloch, N. J., Schweppe, D. K., Huttlin, E. L., & Gygi, S. P. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01539-0 · Cited by 165
Targeted Therapy for Breast Cancer
Mohamed, A., Krajewski, K., Çakar, B., & Ma, C. X. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.07.005 · Cited by 171
The Role of CDK4/6 Inhibition in Breast Cancer
Murphy, C. G., & Dickler, M. N. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0443 · Cited by 135
New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy
Bury, M., Calvé, B. L., Ferbeyre, G., Blank, V., & Lessard, F. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.01.010 · Cited by 144
Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers
Santo, L., Siu, K. T., & Raje, N. S. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.024 · Cited by 142
Endocrine-Resistant Breast Cancer: Mechanisms and Treatment
Hartkopf, A. D., Grischke, E., & Brucker, S. Y. (2020) · Breast Care · doi:10.1159/000508675 · Cited by 149
Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment
Pasha, N., & Turner, N. C. (2021) · Nature Cancer · doi:10.1038/s43018-021-00229-1 · Cited by 143
Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies
Murphy, C. G., & Dickler, M. N. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0121 · Cited by 142
Guarducci, C., Bonechi, M., Benelli, M., Biagioni, C., Boccalini, G., Romagnoli, D., Verardo, R., Schiff, R., Osborne, C. K., Angelis, C. D., et al. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0092-4 · Cited by 153
Bisi, J., Sorrentino, J. A., Roberts, P. J., Tavares, F. X., & Strum, J. C. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0775 · Cited by 135
Yadav, V., Burke, T. F., Huber, L., Van Horn, R. D., Zhang, Y., Buchanan, S. G., Chan, E. M., Starling, J. J., Beckmann, R. P., & Peng, S.-B. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0257 · Cited by 132
Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance
Marina, M. E., & Saavedra, H. I. (2014) · Frontiers in bioscience · doi:10.2741/4212 · Cited by 137
Nemunaitis, J. J., Small, K. A., Kirschmeier, P., Zhang, D., Zhu, Y., Jou, Y.-M., Statkevich, P., Yao, S.-L., & Bannerji, R. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-259 · Cited by 129
Liu, F., & Korc, M. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0562 · Cited by 128
Clark, A. S., Karasic, T. B., DeMichele, A. M., Vaughn, D. J., O’Hara, M. H., Perini, R. F., Zhang, P. J., Lal, P., Feldman, M. D., Gallagher, M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4701 · Cited by 143
Shah, M., Nunes, M. R., & Stearns, V. (2018) · PubMed · Cited by 128
Knudsen, E. S., Kumarasamy, V. M., Nambiar, R., Pearson, J. D., Vail, P. J., Rosenheck, H. R., Wang, J., Eng, K., Bremner, R., Schramek, D., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110448 · Cited by 139
Marra, A., Chandarlapaty, S., & Modi, S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00849-9 · Cited by 157
Witkiewicz, A. K., & Knudsen, E. S. (2014) · Breast Cancer Research · doi:10.1186/bcr3652 · Cited by 125
Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond
García‐Alonso, S., Ocaña, A., & Pandiella, A. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.12.010 · Cited by 140
Epigenetic polypharmacology: A new frontier for epi‐drug discovery
Tomaselli, D., Lucidi, A., Rotili, D., & Mai, A. (2020) · Medicinal Research Reviews · doi:10.1002/med.21600 · Cited by 119
Heilmann, A. M., Perera, R. M., Ecker, V., Nicolay, B. N., Bardeesy, N., Benes, C. H., & Dyson, N. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2923 · Cited by 119
“In cells that express intact pRB, PD-0332991 blocks pRB phosphorylation at sites normally targeted by CDK4/6 (including serines S807/811 and S780) and causes G1 cell-cycle arrest (9, 10).”
BackgroundWang, H., Ou, Q., Li, D., Qin, T., Bao, H., Hou, X., Wang, K., Wang, F., Deng, Q., Jianzhong, L., et al. (2019) · Cancer · doi:10.1002/cncr.32372 · Cited by 124
Zarkada, G., Howard, J. P., Xiao, X., Park, H., Bizou, M., Leclerc, S., Künzel, S. E., Boisseau, B., Li, J., Cagnone, G., et al. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.06.021 · Cited by 134
Concise total syntheses of (–)-jorunnamycin A and (–)-jorumycin enabled by asymmetric catalysis
Welin, E. R., Ngamnithiporn, A., Klatte, M., Lapointe, G., Pototschnig, G., McDermott, M. S. J., Conklin, D. F., Gilmore, C. D., Tadross, P. M., Haley, C. K., et al. (2018) · Science · doi:10.1126/science.aav3421 · Cited by 124
MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21
Vilgelm, A. E., Saleh, N., Shattuck-Brandt, R., Riemenschneider, K., Slesur, L., Chen, S.-C., Johnson, C. A., Yang, J., Blevins, A., Yan, C., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7171 · Cited by 122
O’Brien, N. A., McDonald, K., Luo, T., von Euw, E., Kalous, O., Conklin, D. F., Hurvitz, S. A., di Tomaso, E., Schnell, C., Linnartz, R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2769 · Cited by 130
Palafox, M., Monserrat, L., Bellet, M., Villacampa, G. J., González-Pérez, A., Oliveira, M., Brasó‐Maristany, F., Ibrahimi, N., Kannan, S., Mina, L. B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32828-6 · Cited by 150
Shah, A., Bloomquist, E. W., Tang, S. W., Fu, W., Bi, Y., Liu, Q., Yu, J., Zhao, P., Palmby, T. R., Goldberg, K. B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2369 · Cited by 123
Presti, D., & Quaquarini, E. (2019) · Cancers · doi:10.3390/cancers11091242 · Cited by 126
Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS
Taylor‐Harding, B., Aspuria, P.-J. P., Agadjanian, H., Cheon, D., Mizuno, T., Greenberg, D. N., Allen, J. R., Spurka, L., Funari, V. A., Spiteri, E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2673 · Cited by 122
Are all cyclin-dependent kinases 4/6 inhibitors created equal?
Marra, A., & Curigliano, G. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0121-y · Cited by 123
Preclinical antitumor efficacy of senescence-inducing chemotherapy combined with a nanoSenolytic
Galiana, I., Lozano-Torres, B., Sancho, M., Alfonso, M., Bernardos, A., Bisbal, V., Serrano, M., Martínez-Máñez, R., & Orzáez, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.045 · Cited by 115
Xue, Y., Meehan, B., Macdonald, E. A., Venneti, S., Wang, X. Q. D., Witkowski, L., Jelinic, P., Kong, T., Martínez, D., Morin, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-06958-9 · Cited by 128
Ciruelos, E., Villagrasa, P., Pascual, T., Oliveira, M., Pernas, S., Paré, L., Escrivá-de-Romaní, S., Manso, L., Adamo, B., de Dueñas, E. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0844 · Cited by 119
Targeting cell cycle and hormone receptor pathways in cancer
Comstock, C. E. S., Augello, M. A., Goodwin, J. F., de Leeuw, R., Schiewer, M. J., Ostrander, W. F., Burkhart, R. A., McClendon, A. K., McCue, P. A., Trabulsi, E. J., et al. (2013) · Oncogene · doi:10.1038/onc.2013.83 · Cited by 113
Piezzo, M., Chiodini, P., Riemma, M., Cocco, S., Caputo, R., Cianniello, D., Gioia, G. D., Lauro, V. D., Rella, F. D., Fusco, G., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176400 · Cited by 119
Metadata
- Authors
- Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., Los, G., & Slamon, D. J.
- Affiliations
- University of California, Los Angeles (US)
- Pfizer (United States) (US)
- Corresponding author
- Finn, Richard S
- Venue
- Breast Cancer Research
- Published
- 2009-10-29
- Volume
- 11
- Issue
- 5
- Pages
- R77-R77
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- PMC
- PMC2790859
- OpenAlex
- W2148345265
- Cited by
- 1,398
- References
- 49
- Citations by year
- 2026: 48 · 2025: 76 · 2024: 64 · 2023: 94 · 2022: 115 · 2021: 121 · 2020: 137 · 2019: 128 · 2018: 137 · 2017: 131 · 2016: 105 · 2015: 92 · 2014: 51 · 2013: 42 · 2012: 28
- FWCI
- 15.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Breast Cancer Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Defense (W81XWH)
- Russian Science Foundation
- National Institutes of Health (W81XWH)
- Jonsson Comprehensive Cancer Center
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- palbociclib, CDK4/6 inhibitors, HER2-amplified breast cancer, retinoblastoma protein phosphorylation, cyclin D1, CDKN2A, p16, G0/G1 cell cycle arrest, drug sensitivity, drug resistance, patient selection, breast cancer cell lines
- MeSH terms
- Trastuzumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cell Cycle, Drug Synergism, Humans, Phosphorylation, Piperazines, Pyridines, Receptors, Estrogen, Tamoxifen, Retinoblastoma Protein, Apoptosis, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Gene Expression Profiling, Cell Line, Tumor, Cell Growth Processes, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.